Highbridge Capital Management LLC Has $473,000 Stock Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)

Highbridge Capital Management LLC boosted its holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSIWFree Report) by 9.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 397,825 shares of the company’s stock after acquiring an additional 34,067 shares during the quarter. Highbridge Capital Management LLC’s holdings in TriSalus Life Sciences were worth $473,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in TLSIW. Deerfield Management Company L.P. Series C bought a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $127,000. MSD Partners L.P. bought a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $51,000. Wolverine Asset Management LLC bought a new position in shares of TriSalus Life Sciences during the 4th quarter worth approximately $123,000. Shaolin Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $29,000. Finally, Context Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $27,000.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock traded up $0.05 during mid-day trading on Thursday, hitting $2.15. 2,500 shares of the stock were exchanged, compared to its average volume of 15,233. TriSalus Life Sciences, Inc. has a 12 month low of $0.04 and a 12 month high of $2.23. The company has a 50-day simple moving average of $1.07 and a 200 day simple moving average of $0.90.

TriSalus Life Sciences Profile

(Free Report)

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

See Also

Want to see what other hedge funds are holding TLSIW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TriSalus Life Sciences, Inc. (NASDAQ:TLSIWFree Report).

Institutional Ownership by Quarter for TriSalus Life Sciences (NASDAQ:TLSIW)

Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.